NEWS

  • All
  • Press Release
  • Announcement

2021/07/05Announcement

KinoPharma is pleased to announce that it has decided to initiate the highest dose administration in a multiple-dose clinical trial in patients for cervical dysplasia (CIN, a precursor to cervical cancer) based on the recommendation of the Data Monitoring Committee.

2021/01/13Announcement

Partnership with IWAKI SEIYAKU CO., LTD.

KinoPharma is delighted to announce that we have entered into a partnership with IWAKI SEIYAKU CO., LTD. for the development of drug formulations in the treatment of verruca and the supply of APIs. In conjunction with the partnership, IWAKI SEIYAKU has purchased new shares of the KinoPharma's stock through a private placement.

Along with its parent company IWAKI & CO., LTD., IWAKI SEIYAKU is engaged in the pharmaceutical and fine chemical businesses from research and development to manufacturing and sales of pharmaceuticals in order to contribute to human health and the pharmaceutical industry. In the pharmaceutical business, IWAKI SEIYAKU distinctively provides solutions in the field of dermatological diseases, through the global collaboration with pharmaceutical companies in the development and manufacture of topical products as well as through the manufacturing and sales of their dermatological product line.

KinoPharma is developing a new concept of antiviral drugs that target host factors to inhibit viral replication. The lead program is in Phase I/II for the treatment of cervical intraepithelial neoplasia (CIN) which is human papillomavirus (HPV) infection causing cervical cancer. KinoPharma is also developing therapeutic agents for various diseases caused by HPV infection, such as verruca vulgaris and condyloma acuminatum.

The partnership is expected to strengthen the supply system of APIs for antiviral drugs and accelerate the development of anti-HPV drugs in the field of dermatology, which will lead to further development and growth of KinoPharma.

2020/10/05Announcement

KinoPharma is delighted to announce the enrollment of the first patient in a multiple-ascending-dose study in the Phase I/II clinical trial for cervical dysplasia (CIN, a precursor to cervical cancer).

2020/09/24Announcement

KinoPharma is pleased to announce that it has decided to initiate a multiple-dose clinical trial in patients for cervical dysplasia (CIN, a precursor to cervical cancer), which has been ongoing since July of this year, based on the recommendation of the Data Monitoring Committee.

2020/07/06Press Release

Kinopharma is delighted to announce the registration of the first subject in phase 1/2 clinical studies in Korea evaluating the safety and efficacy of the anti-HPV agent, Kinopharma’s flagship program, in patients with cervical intraepithelial neoplasia (CIN).

Cervical intraepithelial neoplasia (CIN) is human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer. Currently, there are no approved antiviral drugs for the treatment of CIN. Our clinical candidate anti-HPV agent is intended to treat CIN by removing any types of HPV from the cervix. We aim for the fastest approval of the anti-HPV agent.

2020/06/17Announcement

Joint research on bovine papillomatosis with Obihiro University of Agriculture and Veterinary Medicine

Since last year, Kinopharma and Obihiro University of Agriculture and Veterinary Medicine (Associate Professor Tomas Acosta) have been engaged in joint research on bovine papillomatosis which is caused by Bovine Papillomavirus infection, using Kinopharma’s antiviral drug candidates. Based on the knowledge obtained last year, we have agreed to proceed with further joint research for verifying the effectiveness this year.
It is known that bovine papillomatosis is an infectious disease caused by bovine papilloma virus, and It has brought the problems of difficulty in milking and falling of dairy cow market price for the livestock industry. Bovine papillomavirus belongs to papillomaviridae similar to human papillomavirus, and Kinopharma has commenced the development of treatment for human papillomavirus infections such as cervical intraepithelial neoplasia (CIN) and common warts (viral warts).

2020/02/28Announcement

At the Kyoto University Life Science Showcase held in San Diego, CEO Kuroishi made a presentation on our antiviral drug projects.

View the press release (PDF)Kyoto University Life Science Showcase 2020, San Diego

2020/02/25Announcement

KinoPharma is ready for providing its proprietary "pan-antiviral drug candidate" for investigations against Coronaviruses (COVID-19).

2020/02/20Announcement

A clinical trial plan for cervical dysplasia was approved by the Korean Ministry of Food and Drug Safety (MFDS).

2020/01/14Press Release

ASKA Pharmaceutical and KinoPharma Entered into Option Agreement for Treatment of Cervical Dysplasia.

View the press release (PDF)

2019/06/07Announcement

Kyoto University started an investigator-initiated trial to treat cervical intraepithelial neoplasia, a precursor to cervical cancer, by administering a candidate anti-HPV drug provided by KinoPharma.

Novel treatment for cervical cancer precursor goes into clinical trial

2018/08/29Press Release

We launched a collaborative research project for exploring new drug development for alzheimer’s disease with National Institutes for Quantum and Radiological Science and Technology.

View the press release (PDF)

2017/09/28Announcement

Our project "antiviral drug development for Human Papillomavirus(HPV), which causes cervical cancer", was adopted as a grant of the KYOTO Industrial Support Organization 21.

2017/08/24Announcement

Mr. Kuroishi, CEO,showed the status of our business regarding development of the anti-virus agentat the "IPO Caravan" sponsored by the Mitsubishi UFJ Trust Bank.

2017/08/04Announcement

Mr. Kuroishi, CEO, had an oral presentation at the "1st Healthcare Venture Conference KYOTO" held at the Kyoto Research Park.

2017/07/01Announcement

We established the Exploratory Research Laboratory at the Innovation Hub Kyoto of Kyoto University.

2017/03/03Announcement

NEDO Research Fund has been granted.

2020/07/06Press Release

Kinopharma is delighted to announce the registration of the first subject in phase 1/2 clinical studies in Korea evaluating the safety and efficacy of the anti-HPV agent, Kinopharma’s flagship program, in patients with cervical intraepithelial neoplasia (CIN).

Cervical intraepithelial neoplasia (CIN) is human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer. Currently, there are no approved antiviral drugs for the treatment of CIN. Our clinical candidate anti-HPV agent is intended to treat CIN by removing any types of HPV from the cervix. We aim for the fastest approval of the anti-HPV agent.

2020/01/14Press Release

ASKA Pharmaceutical and KinoPharma Entered into Option Agreement for Treatment of Cervical Dysplasia.

View the press release (PDF)

2018/08/29Press Release

We launched a collaborative research project for exploring new drug development for alzheimer’s disease with National Institutes for Quantum and Radiological Science and Technology.

View the press release (PDF)

2021/07/05Announcement

KinoPharma is pleased to announce that it has decided to initiate the highest dose administration in a multiple-dose clinical trial in patients for cervical dysplasia (CIN, a precursor to cervical cancer) based on the recommendation of the Data Monitoring Committee.

2021/01/13Announcement

Partnership with IWAKI SEIYAKU CO., LTD.

KinoPharma is delighted to announce that we have entered into a partnership with IWAKI SEIYAKU CO., LTD. for the development of drug formulations in the treatment of verruca and the supply of APIs. In conjunction with the partnership, IWAKI SEIYAKU has purchased new shares of the KinoPharma's stock through a private placement.

Along with its parent company IWAKI & CO., LTD., IWAKI SEIYAKU is engaged in the pharmaceutical and fine chemical businesses from research and development to manufacturing and sales of pharmaceuticals in order to contribute to human health and the pharmaceutical industry. In the pharmaceutical business, IWAKI SEIYAKU distinctively provides solutions in the field of dermatological diseases, through the global collaboration with pharmaceutical companies in the development and manufacture of topical products as well as through the manufacturing and sales of their dermatological product line.

KinoPharma is developing a new concept of antiviral drugs that target host factors to inhibit viral replication. The lead program is in Phase I/II for the treatment of cervical intraepithelial neoplasia (CIN) which is human papillomavirus (HPV) infection causing cervical cancer. KinoPharma is also developing therapeutic agents for various diseases caused by HPV infection, such as verruca vulgaris and condyloma acuminatum.

The partnership is expected to strengthen the supply system of APIs for antiviral drugs and accelerate the development of anti-HPV drugs in the field of dermatology, which will lead to further development and growth of KinoPharma.

2020/10/05Announcement

KinoPharma is delighted to announce the enrollment of the first patient in a multiple-ascending-dose study in the Phase I/II clinical trial for cervical dysplasia (CIN, a precursor to cervical cancer).

2020/09/24Announcement

KinoPharma is pleased to announce that it has decided to initiate a multiple-dose clinical trial in patients for cervical dysplasia (CIN, a precursor to cervical cancer), which has been ongoing since July of this year, based on the recommendation of the Data Monitoring Committee.

2020/06/17Announcement

Joint research on bovine papillomatosis with Obihiro University of Agriculture and Veterinary Medicine

Since last year, Kinopharma and Obihiro University of Agriculture and Veterinary Medicine (Associate Professor Tomas Acosta) have been engaged in joint research on bovine papillomatosis which is caused by Bovine Papillomavirus infection, using Kinopharma’s antiviral drug candidates. Based on the knowledge obtained last year, we have agreed to proceed with further joint research for verifying the effectiveness this year.
It is known that bovine papillomatosis is an infectious disease caused by bovine papilloma virus, and It has brought the problems of difficulty in milking and falling of dairy cow market price for the livestock industry. Bovine papillomavirus belongs to papillomaviridae similar to human papillomavirus, and Kinopharma has commenced the development of treatment for human papillomavirus infections such as cervical intraepithelial neoplasia (CIN) and common warts (viral warts).

2020/02/28Announcement

At the Kyoto University Life Science Showcase held in San Diego, CEO Kuroishi made a presentation on our antiviral drug projects.

View the press release (PDF)Kyoto University Life Science Showcase 2020, San Diego

2020/02/25Announcement

KinoPharma is ready for providing its proprietary "pan-antiviral drug candidate" for investigations against Coronaviruses (COVID-19).

2020/02/20Announcement

A clinical trial plan for cervical dysplasia was approved by the Korean Ministry of Food and Drug Safety (MFDS).

2019/06/07Announcement

Kyoto University started an investigator-initiated trial to treat cervical intraepithelial neoplasia, a precursor to cervical cancer, by administering a candidate anti-HPV drug provided by KinoPharma.

Novel treatment for cervical cancer precursor goes into clinical trial

2017/09/28Announcement

Our project "antiviral drug development for Human Papillomavirus(HPV), which causes cervical cancer", was adopted as a grant of the KYOTO Industrial Support Organization 21.

2017/08/24Announcement

Mr. Kuroishi, CEO,showed the status of our business regarding development of the anti-virus agentat the "IPO Caravan" sponsored by the Mitsubishi UFJ Trust Bank.

2017/08/04Announcement

Mr. Kuroishi, CEO, had an oral presentation at the "1st Healthcare Venture Conference KYOTO" held at the Kyoto Research Park.

2017/07/01Announcement

We established the Exploratory Research Laboratory at the Innovation Hub Kyoto of Kyoto University.

2017/03/03Announcement

NEDO Research Fund has been granted.